Mohammad Hossein Soltanzadeh,MD,
ID, prof. of
Pediatrics , Shahid Beheshti
of Medical Science, Tehran , IRAN
The US Food &
Drug Administration ( FDA ) has expanded the indication for the
quadrivalent meningococcal vaccine ( Menveo , Novartis ) to
infants and toddlers from age 2 months
, the company announced .
protects against invasive disease caused by common Neisseria
serogroups A,C, Y , and W-135.
reported , Menveno has been available for use in adolescents and
adults ( 11-55 years of age since February 2010 ) and children (
2-10 years of age since January 2011 ) .
expanded indication, “ we now have the opportunity to help
protect our infants against 4 strains of meningococcal disease
earlier , when they are most vulnerable “ he said .
Studies show that infants younger than 7 months are the age
group most vulnerable to meningococcal disease in the United
states . In their first year of life , infants are more than
7 times more likely to contract the disease than 14 to 24 year
olds . O f the infants who contract the disease , more than 10%
will die from it , and of those who do survive , roughly in 5
will suffer permanent adverse effects.
The FDA,s decision to expand use of the vaccine to infants from
2 months of age
Menveo is currently registered in more than 50 countries for
active immunization to prevent invasive meningococcal disease
caused by N. meningitides serogroups
A,C,W-135 , and Y
no vaccine is approved to protect against meningitis serogroup B
Invasive infection usually results in meningogoccsemia ,
meningitis , or both , Onset oftens abrupt in meningococcemia ,
with fever , chills ,malaise , prostration, and a rash that
initially can be macular, maculopapular , or petechial .The
progression of disease often is rapid . In fulminant cases
(Waterhouse –Friderichsen syndrome )
purpura , disseminated intravascular coagulation(DIC) , shock
,coma, and death can ensue despite appropriate therapy . The
signs and symptoms are the same of other meningitis.
Sequele associated with meningococcal disease occur in 11 % to
19% of patients and include : hearing loss , neurologic
disability , digit or limb amputations , and skin scaring ,
sometimes requiring skin gruafts.
gram – negative diplococcus with at least 13 serogroups.